News
Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease
News
Blood pressure values less than 140/90mmHg tied to increased mortality risk for octogenarians
News
A recently published report describes the case of a patient who developed non-ischemic cardiomyopathy following initiation of gabapentin therapy for pain management.
News
Gelesis announced that the Food and Drug Administration (FDA) has cleared Plenity (Gelesis100) to aid in weight management for overweight and obese adults, in conjunction with diet and exercise. Available in capsule form, Plenity, a non-systemic, superabsorbent hydrogel, is intended for use in adults with a body mass index (BMI) of 25–40kg/m2 and is taken…
News
According to the results of a systematic review, there is a lack of evidence supporting the potential health benefits of kombucha, a fermented tea beverage, in humans.
Slideshow
A 51-year-old woman requests treatment for thickening of the skin of her nose. The condition has been gradually worsening over the past 2 years. She drinks alcohol in moderation and does not smoke. She takes medication for hypertension. Prior treatments for her nasal condition include doxycycline, metronidazole, and topical ivermectin, all of which were ineffectual.
Drugs in the Pipeline
United Therapeutics reported that following disappointing results from the BEAT study (NCT01908699), the company has decided to discontinue the development of esuberaprost for the treatment of pulmonary arterial hypertension.
News
As part of the ongoing safety investigation of potentially carcinogenic impurities detected in angiotensin II receptor blocker (ARB) medications.
News
The Food and Drug Administration (FDA) has approved generic versions of the endothelin receptor antagonist Letairis (ambrisentan; Gilead) for the first time.
News
The Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Siponimod, a sphingosine-1-phosphate (S1P) receptor modulator, binds with high affinity to S1P receptors 1 and 5. It blocks the capacity of…